ЗОФЕНОПРИЛ – КАРДИОПРОТЕКТИВНЫЙ ИНГИБИТОР АНГИОТЕНЗИНA ПРЕВРАЩАЮЩЕГО ФЕРМЕНТА: КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ И ОПЫТ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ

1. Subissi A., Evangelista E., Giachetti A. Preclinical profile of zofenopril: An angiotensin converting enzyme inhibitor with pecular cardioprotective properties. Cardiovascular Drug. Reviews 1999; 17: 115-133.

2. Borghi C., Ambrosioni E. The role of zofenopril in the treatment of cardiovascular diseases. Milano, 2001.

3. Borghi C., Bacchelli S., Esposti D.D., Ambrosioni E. A review of the angiotensin converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Expert Opinion on Pharmacotherapy 2004; 5 (9): 1965-1977.

4. Opie L.H. Angiotensin converting enzyme inhibitors. 3th edition. New York, 1999.

5. Сидоренко Б.А., Преображенский Д.В. Ингибиторы ангиотензинпревращающего фермента. М., 1998.

6. Преображенский Д.В., Сидоренко Б.А., Батыралиев Т.А. Медикаментозное лечение хронической сердечной недостаточности. М., 2004.

7. Cushman D.W., Wang F.L., Fung W.C. et al. Comparisons in vitro, ex vivo, and in vivo of the the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Brit. J. Clin. Pharmacol. 1989; 28 (suppl. 2): 115S-131S.

8. Cushman D.W., Wang F.L., Fung W.C. et al. Differentiation of angiotensin converting enzyme (ACE) inhibitors by selective inhibition of ACE in physiologically important target organs. Amer. J. Hypertension 1989; 2 (4): 294-306.

9. Napoli C., Sica V., de Nigris F. et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative syress and improves the nitric oxide pathway in patients with essential hypertension. Amer. Heart. J. 200; 148 e5 (pp. K1-K7).

10. Borghi C., Bacchelli S., Esposti D.D., et al., on behalf of the SMILE study investigators. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute myocardial infarction in patients with arterial hypertension. Amer. J. Hypertension 1999; 12: 665-672.

11. Borghi C., Bacchelli S., Esposti D.D., et al., on behalf of the SMILE study investigators. Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction. Diabetes Care 2003; 26: 1862-1868.

12. Borghi С., Ambrosioni E., on behalf of the SMILE-2 working party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: Results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Amer. Heart J. 2003; 145 (1): 80-87.

13. Brown N.J., Vaughan D.E. Angiotensin converting enzyme inhibitors. Circulation 1998; 97 (14): 1411-1420.

14. Преображенский Д.В., Сидоренко Б.А., Батыралиев Т.А. Ингибиторы АПФ и AT1-блокаторы в клинической практике. Часть 3. М., 2004.

15. Сидоренко Б.А., Преображенский Д.В. Диагностика и лечение артериальной гипертензии. Часть 3. М., 2001.

16. Borghi С., Ambrosioni Е. Zofenopril. Una rassegna sull'evidenza dei suoi effettti vantaggiosio nell'ipertensione e nell'infarto miocardico acuto (in Italian). Clin. Drug Invest. 2000; 2 (5): 371-384.

17. Malacco E., Giusti A., on behalf of the Zofenopril Study Group. Once-daily zofenopril provides 24-hour ambulatory blood pressures control in hypertensive patients aged under 65 years. Amer. J. Hypertension 1998; 11 (4 part 2): 70.

18. Malacco E., Castiglioni G., Corradi L. et al. Dose-response relationship of zofenopril in essential hypertension. Clin. Drug Invest. 2002; 22(1): 9-15.

19. Lacourciere Y., Provencher P. Comparative effects of zofenopril and hydrochlorthiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. Brit. J. Clin. Pharmacol. 1989; 2 (11): 861-864.

20. Giusti A., Bertolotti M., Llabres S. et al. Comparison of the efficacy of zofenopril or enalapril in patients with mild to moderate hypertension. Amer. J. Hypertension 1999; 12 (4 part 2): 28.

21. Giusti A., Bertolotti M., Clark W.I.C. et al. The efficacy and safety of zofenopril compared to amlodipine in patients with mild to moderate hypertension. Amer. J. Hypertension 1999; 12 (4 part 2): 140.

22. Meredith P.A.//Role of through to peak efficacy in the evaluation of antihypertensive efficacy. J. Hypertension, 1998; 16 (suppl. 1): S59-S64.